Marc Serota, MD, FAAD, discusses highlights from his lecture on Immunology 101 at the 2021 Elevate-Derm Conference

In this video

Serota, who is triple board certified in allergy/immunology, pediatrics, and dermatology, explains how he gives patients "30 seconds on the pathophysiology" using a military analogy: the immune system is like an army, and one battalion has gone rogue. If you "jam the radio signals" of just that battalion, you can shut off the disease process while leaving the rest of the military to do its job — the soldiers are all still there waiting for a go signal that never comes. He argues this framing helps patients understand how a treatment works and improves compliance.

He also addresses what to do when inflammatory skin diseases have overlapping features. Rather than staying stuck, he advocates hedging your bet on the pathway you think is right — eczema/dermatitis versus psoriasis — targeting that pathway, then reassessing at week 12 or 16 to see if the patient improved. In murky cases, "the treatment can prove your diagnosis." On urticaria, he prefers the label chronic autoimmune urticaria, noting that 30–50% of chronic cases have autoantibodies triggering mast cells independently of any external trigger, consistent with the two-to-one female predominance seen in autoimmune conditions.

  • Explain therapy to patients as "jamming the radio signal" of the one immune battalion that has gone rogue, leaving the rest of the immune system intact.
  • When inflammatory diseases overlap, commit to the pathway you think is right, treat it, and reassess efficacy at week 12–16 — response confirms you targeted the correct pathway.
  • If there's no improvement, reconsider whether you were targeting the wrong pathway and switch strategy.
  • Roughly 30–50% of chronic urticaria is autoimmune, driven by autoantibodies that trigger mast cells without any external trigger — hence a two-to-one female predominance.
  • Rule out mimics and triggers in acute urticaria, but once it's chronic, it's more likely than not an autoimmune process rather than a hunt for a single elusive allergen.